Research and Clinical Application of Adenovirus (AdV), 3rd Edition
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Human Virology and Viral Diseases".
Deadline for manuscript submissions: 25 May 2025 | Viewed by 77
Special Issue Editor
Interests: adenovirus; oncolytic; cancer; models; gene; therapy; delivery; translation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The concept behind using viruses to fight human diseases is very straightforward: for millions of years, they have been delivering their genes to different types of mammalian and human cells. Indeed, virus-based gene therapy is a growing area of modern medicine, as viruses have the potential to overcome the limitations of conventional therapeutic approaches.
Adenovirus (AdV) is one of the most versatile viral backbones with applications ranging from gene delivery and treatment of monogenic diseases to vaccination and cancer therapy. Adenoviruses can target a broad spectrum of both dividing and non-dividing cells, do not integrate into host DNA, have high in vivo transduction capacity, and are well characterized, thereby allowing for countless modifications of their genetic structure. The first AdV-based therapy took place in 1956, when 30 patients with cervical carcinoma were treated with adenoidal–pharyngeal–conjunctival virus, now known as an adenovirus. After a turbulent past full of medical achievements and failures, the stigma related to adenovirus has been gradually replaced by the wide acceptance of the feasibility and safety of AdV-based therapeutics. It is difficult to overestimate the value of AdV during the COVID-19 pandemic as, to date, AdV represents the most effective viral vector platform for anti-SARS-CoV-2 vaccines. The recent clinical successes have also demonstrated the promise of tumor-selective, infectivity-improved oncolytic adenoviruses for cancer gene therapy and highlighted their role in inducing anticancer immunity.
This third Special Issue discusses the latest advances in adenovirus research and how AdV can treat human disease. The scope of this Special Issue includes but is not limited to:
- The molecular and cellular mechanisms of adenovirus infection and pathogenesis, including the molecular determinants of cell and tissue tropism, life cycle, transmission in the host, and mechanisms of cell death and tissue damage;
- Structure-based investigations of virus and virus capsid protein associations with cell receptors and innate immune molecules, as well as modulation and evasion of the host’s immune defense;
- Applications range from basic molecular tools to gene therapy, oncolytic virus therapy, immunotherapy, and vaccine development.
Dr. Julia Davydova
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adenovirus
- gene therapy
- cancer
- oncolytic
- vaccine
- delivery
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
Related Special Issues
- Research and Clinical Application of Adenovirus (AdV) in Viruses (10 articles)
- Research and Clinical Application of Adenovirus (AdV), 2nd Edition in Viruses (11 articles)
